Close Menu

North America

The FDA had previously approved neratinib as an extended adjuvant therapy for patients with early-stage HER2-overexpressed or amplified breast cancer, following adjuvant treatment with trastuzumab.

The study showed that patients with targetable genomic markers, especially HER2 alterations, responded well to chemotherapy-free treatments.

With EMR upgrades, Penn and Rush now have structured genomic data informing clinical decision support in their precision oncology programs, but much work remains.

A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.

The analysis also suggested ways to outwit these mechanisms based on the degree of immune cell infiltration into the tumor. 

The study of cancer immunity biomarkers revealed complex immune profiles for most tumors, suggesting the need for customized combinations of immunotherapies.

The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.

Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.

Extending a prior agreement with the drugmaker, Personalis will use its DNA/RNA platform to identify both predictive biomarkers and resistance mechanisms.

The company filed the application based on the PAOLA-1 data, which showed HRD-positive ovarian cancer patients saw pronounced benefit from the combo.

Pages